Magenta therapeutics reports recent business highlights and q2 results

Magenta therapeutics reports recent business highlights and second quarter financial results.magenta therapeutics inc - mgta-145 to move into phase 2 trials in autologous and allogeneic transplant in 2020.magenta therapeutics inc - ended quarter with $176.5 million in cash, cash equivalents and marketable securities.magenta therapeutics inc qtrly loss per share 48 cents.
DNTH Ratings Summary
DNTH Quant Ranking